Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ji Ma, Robbert Boudewijns, Lorena Sanchez-Felipe, Niraj Mishra, Thomas Vercruysse, Dieudonné Buh Kum, Hendrik Jan Thibaut, Johan Neyts & Kai Dallmeier. (2021) Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice. Emerging Microbes & Infections 10:1, pages 2279-2290.
Read now
Read now
Articles from other publishers (32)
Chenxi Li, Linjie Zhang, Xuan Chen, Daoyuan Jiang, Jingbo Hu, Jinyao Guo, Jingjing Ding, Xue Jiao, Wenbin Bao & Yanhua Li. (2023) Evaluation of the genotype I Japanese encephalitis virus as a stable viral vector for foreign gene expression. Antiviral Research 216, pages 105652.
Crossref
Crossref
Viktor Lemmens, Lara Kelchtermans, Sarah Debaveye, Winston Chiu, Thomas Vercruysse, Ji Ma, Hendrik Jan Thibaut, Johan Neyts, Lorena Sanchez-Felipe & Kai Dallmeier. (2023) YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge. npj Vaccines 8:1.
Crossref
Crossref
J. Erin Staples, Emily H. Davis, Thomas P. Monath & Alan D.T. Barrett. 2023. Plotkin's Vaccines. Plotkin's Vaccines
1251
1321.e19
.
Hongyu Chen, Hongqi Liu & Xiaozhong Peng. (2022) Reverse genetics in virology: A double edged sword. Biosafety and Health 4:5, pages 303-313.
Crossref
Crossref
Ji Ma, Michael Bright Yakass, Sander Jansen, Bert Malengier-Devlies, Dominique Van Looveren, Lorena Sanchez-Felipe, Thomas Vercruysse, Birgit Weynand, Mahadesh Prasad Arkalagud Javarappa, Osbourne Quaye, Patrick Matthys, Tania Roskams, Johan Neyts, Hendrik Jan Thibaut & Kai Dallmeier. (2022) Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models. eBioMedicine 83, pages 104240.
Crossref
Crossref
Li-Hsin Li, Laurens Liesenborghs, Lanjiao Wang, Marleen Lox, Michael Bright Yakass, Sander Jansen, Ana Lucia Rosales Rosas, Xin Zhang, Hendrik Jan Thibaut, Dirk Teuwen, Johan Neyts, Leen Delang & Kai Dallmeier. (2022) Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Molecular Therapy - Methods & Clinical Development 25, pages 215-224.
Crossref
Crossref
Shaleesa Ledlie, Christina Ricci, Chunshen Pan, Andrey Rojas, Alena Khromava & Lin Li. (2022) Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases. Vaccine 40:5, pages 742-751.
Crossref
Crossref
Laura Seldeslachts, Christopher Cawthorne, Suzanne F. Kaptein, Robbert Boudewijns, Hendrik Jan Thibaut, Lorena Sanchez Felipe, Sapna Sharma, Georg Schramm, Birgit Weynand, Kai Dallmeier & Greetje Vande Velde. 2022. Vaccine Design. Vaccine Design
177
192
.
Nadia Oreshkova, Sebenzile K. Myeni, Niraj Mishra, Irina C. Albulescu, Tim J. Dalebout, Eric J. Snijder, Peter J. Bredenbeek, Kai Dallmeier & Marjolein Kikkert. (2021) A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses. Vaccines 9:12, pages 1492.
Crossref
Crossref
Terna Nomhwange, Anne Eudes Jean Baptiste, Obi Ezebilo, Joseph Oteri, Lois Olajide, Kizito Emelife, Shehu Hassan, Erdoo R. Nomhwange, Kennedy Adejoh, Faith Ireye, Eyo E. Nora, Adamu Ningi, Blaise Bathondeli & Oyewale Tomori. (2021) The resurgence of yellow fever outbreaks in Nigeria: a 2-year review 2017–2019. BMC Infectious Diseases 21:1.
Crossref
Crossref
Robbert Boudewijns, Ji Ma, Johan Neyts & Kai Dallmeier. (2021) A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice. JHEP Reports 3:4, pages 100295.
Crossref
Crossref
Rong Zhao, Meiyue Wang, Jing Cao, Jing Shen, Xin Zhou, Deping Wang & Jimin Cao. (2021) Flavivirus: From Structure to Therapeutics Development. Life 11:7, pages 615.
Crossref
Crossref
O. D. Popova, O. V. Zubkova, T. A. Ozharovskaia, D. I. Zrelkin, D. V. Voronina, I. V. Dolzhikova, D. V. Shcheblyakov, B. S. Naroditsky, D. Yu. Logunov & A. L. Gintsburg. (2021) Review of candidate vaccines for the prevention of Lassa fever. Problems of Virology 66:2, pages 91-102.
Crossref
Crossref
Lorena Sanchez-Felipe, Thomas Vercruysse, Sapna Sharma, Ji Ma, Viktor Lemmens, Dominique Van Looveren, Mahadesh Prasad Arkalagud Javarappa, Robbert Boudewijns, Bert Malengier-Devlies, Laurens Liesenborghs, Suzanne J. F. Kaptein, Carolien De Keyzer, Lindsey Bervoets, Sarah Debaveye, Madina Rasulova, Laura Seldeslachts, Li-Hsin Li, Sander Jansen, Michael Bright Yakass, Babs E. Verstrepen, Kinga P. Böszörményi, Gwendoline Kiemenyi-Kayere, Nikki van Driel, Osbourne Quaye, Xin Zhang, Sebastiaan ter Horst, Niraj Mishra, Ward Deboutte, Jelle Matthijnssens, Lotte Coelmont, Corinne Vandermeulen, Elisabeth Heylen, Valentijn Vergote, Dominique Schols, Zhongde Wang, Willy Bogers, Thijs Kuiken, Ernst Verschoor, Christopher Cawthorne, Koen Van Laere, Ghislain Opdenakker, Greetje Vande Velde, Birgit Weynand, Dirk E. Teuwen, Patrick Matthys, Johan Neyts, Hendrik Jan Thibaut & Kai Dallmeier. (2020) A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature 590:7845, pages 320-325.
Crossref
Crossref
Roger Hewson. 2021. Human Viruses: Diseases, Treatments and Vaccines. Human Viruses: Diseases, Treatments and Vaccines
605
628
.
Sophia M. Vrba, Natalie M. Kirk, Morgan E. Brisse, Yuying Liang & Hinh Ly. (2020) Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats. Vaccines 8:4, pages 680.
Crossref
Crossref
Robin D.V. Kleinert, Eduardo Montoya-Diaz, Tanvi Khera, Kathrin Welsch, Birthe Tegtmeyer, Sebastian Hoehl, Sandra Ciesek & Richard J.P. Brown. (2019) Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus. Viruses 11:10, pages 960.
Crossref
Crossref
B Afrough, S Dowall & R Hewson. (2019) Emerging viruses and current strategies for vaccine intervention. Clinical and Experimental Immunology 196:2, pages 157-166.
Crossref
Crossref
Khairunnisa Ghaffar, Lisa Ng & Laurent Renia. (2018) Fast Tracks and Roadblocks for Zika Vaccines. Vaccines 6:4, pages 77.
Crossref
Crossref
Ian R. Humphreys & Sarah Sebastian. (2018) Novel viral vectors in infectious diseases. Immunology 153:1, pages 1-9.
Crossref
Crossref
J. Erin Staples, Thomas P. Monath, Mark D. Gershman & Alan D.T. Barrett. 2018. Plotkin's Vaccines. Plotkin's Vaccines
1181
1265.e20
.
Jae-Sung Yu, Hua-Xin Liao, Jamie Pritchett, Cindy Bowman, Callie Vivian, Robert Parks, Shi-Mao Xia, Melissa Cooper, Wilton B Williams, Mattia Bonsignori, Steven G. Reed, Meng Chen, Nathan Vandergrift, Charles M. Rice & Barton F. Haynes. (2017) Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. Journal of Virological Methods 249, pages 85-93.
Crossref
Crossref
TELISSA C. KASSAR, TEREZA MAGALHÃES, JOSÉ V.J. S. JÚNIOR, AMANDA G.O. CARVALHO, ANDRÉA N.M.R. DA SILVA, SABRINA R.A. QUEIROZ, GIOVANI R. BERTANI & LAURA H.V.G. GIL. (2017) Construction and characterization of a recombinant yellow fever virus stably expressing Gaussia luciferase. Anais da Academia Brasileira de Ciências 89:3 suppl, pages 2119-2130.
Crossref
Crossref
Cristina Possas, Patricia Brasil, Mauro CA Marzochi, Amilcar Tanuri, Reinaldo M Martins, Ernesto TA Marques, Myrna C Bonaldo, Antonio GP Ferreira, Ricardo Lourenço-de-Oliveira, Rita Maria R Nogueira, Patricia C Sequeira, Keyla BF Marzochi & Akira Homma. (2017) Zika puzzle in Brazil: peculiar conditions of viral introduction and dissemination - A Review. Memórias do Instituto Oswaldo Cruz 112:5, pages 319-327.
Crossref
Crossref
Florian Douam, Gabriela Hrebikova, Yentli E. Soto Albrecht, Julie Sellau, Yael Sharon, Qiang Ding & Alexander Ploss. (2017) Single-cell tracking of flavivirus RNA uncovers species-specific interactions with the immune system dictating disease outcome. Nature Communications 8:1.
Crossref
Crossref
Natalie D. Collins & Alan D. T. Barrett. (2017) Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day. Current Infectious Disease Reports 19:3.
Crossref
Crossref
C.L. Parks. 2017. Human Vaccines. Human Vaccines
25
63
.
Li-Chen Yen, Jia-Teh Liao, Hwei-Jen Lee, Wei-Yuan Chou, Chun-Wei Chen, Yi-Ling Lin & Ching-Len Liao. (2016) The C Terminus of the Core β-Ladder Domain in Japanese Encephalitis Virus Nonstructural Protein 1 Is Flexible for Accommodation of Heterologous Epitope Fusion. Journal of Virology 90:3, pages 1178-1189.
Crossref
Crossref
Ali H. Ellebedy & Rafi Ahmed. 2016. The Vaccine Book. The Vaccine Book
283
310
.
Pedro Paulo de Abreu Manso, Barbara C. E. P. Dias de Oliveira, Patrícia Carvalho de Sequeira, Yuli Rodrigues Maia de Souza, Jessica Maria dos Santos Ferro, Igor José da Silva, Luzia Fátima Gonçalves Caputo, Priscila Tavares Guedes, Alexandre Araujo Cunha dos Santos, Marcos da Silva Freire, Myrna Cristina Bonaldo & Marcelo Pelajo-Machado. (2015) Yellow Fever 17DD Vaccine Virus Infection Causes Detectable Changes in Chicken Embryos. PLOS Neglected Tropical Diseases 9:9, pages e0004064.
Crossref
Crossref
Jonas D. Albarnaz, Leonardo C. De Oliveira, Alice A. Torres, Rafael M. Palhares, Marisa C. Casteluber, Claudiney M. Rodrigues, Pablo L. Cardozo, Aryádina M.R. De Souza, Carolina C. Pacca, Paulo C.P. Ferreira, Erna G. Kroon, Maurício L. Nogueira & Cláudio A. Bonjardim. (2014) MEK/ERK activation plays a decisive role in yellow fever virus replication: Implication as an antiviral therapeutic target. Antiviral Research 111, pages 82-92.
Crossref
Crossref
Christopher Stobart & Martin Moore. (2014) RNA Virus Reverse Genetics and Vaccine Design. Viruses 6:7, pages 2531-2550.
Crossref
Crossref